The PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines) project, funded by IMI-JU 2, was officially launched in Brussel on April 10th. The PARADIGM consortium is led by the European Patients’ Forum and EFPIA and gathers 34 partners comprising patient organisations, regulatory bodies, universities, non-for-profit organisations, SMEs, trade associations and pharmaceutical companies.
PARADIGM’s mission is to provide a unique framework that enables sustainable patient engagement and demonstrates the ‘return on the engagement’ for all players. PARADIGM will build on existing tools to integrate the needs, perspectives and expectations of all actors involved and will provide a sustainable roadmap for patient engagement.
The project kicked off with the 1st Open Patient Engagement Forum, coorganised by EUPATI and PFMD. The Forum was enriched by interactive workshops and participative Q/A sessions. This event showed the collaborative spirit and commitment of all involved organisations towards the achievement of the PARADIGM’s aim and objectives. “For SYNAPSE this is a great opportunity to meaningfully contribute to strengthen the connection between drug discovery research and the well-being of patients and citizens”, says Synapse CEO, Eva Molero that attended the meeting.
“The First Open Forum on Patient Engagement is a stepping stone toward synergies and alignment between the project partners and extended patient engagement community. In the coming months, PARADIGM will invite researchers, patients, regulators, HTA bodies and all other biomedical research players to join the extended project community and engage to provide different perspective and input,” says Mathieu Boudes, PARADIGM Project Coordinator. “The project will promote two more Open Forum on Patient Engagement, that will be open to other initiatives to contribute.”
More about PARADIGM at www.imi-paradigm.eu.
More about EUPATI at www.eupati.eu.
More about PFMD here.